This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Wednesday, October 6, 2010
InterMune Sells Hep C Drug Rights To Roche
SAN FRANCISCO -- InterMune Inc, said late Wednesday it sold worldwide rights to its experimental Hepatitis C drug danoprevir to Roche Holding AG for $175 million cash. The sale ends a 2006 collaboration agreement between the two companies.
No comments:
Post a Comment